Environment, Health and Safety
Performance
Reporting our performance and impacts drives continuous improvement and communicates GSK's global EHS impacts to stakeholders. Internally, we use the data to inform senior management, to identify areas for improvement, to set and refine targets and to raise employees' awareness of EHS issues.
EHS performance at GSK is measured using a series of EHS performance indicators selected based on
-
industry benchmarking and best practice
-
assessment and prioritisation of our operations and our areas of greatest emissions
-
guidelines set by external technical and professional organisations
In 2003 we collected environmental data from all 97 global manufacturing sites, 27 pharmaceutical and consumer healthcare research & development facilities, 5 of 7 distribution centres, 1 drinks manufacturing facility and 8 of 11 general office buildings. We collected health and safety data from all of these locations as well as from 59 of our 67 sales offices. An intranet data collection tool was used to collect and collate the global data.
In addition to the EHS data collected from sites, we collected GSK business air travel from Global Procurement, US fleet injury and illness information from Employee Health Management and product freight distance from Global Distribution. We also continued a pilot programme, initiated in 2002, to collect core EHS data from major contract manufacturers. In 2003 we collected core EHS data from seven major contract manufacturers.
We continue to rationalise our manufacturing network and site closures, which may occur over several months, continue. Depending on the timing of closures, we continue to collect EHS data from them and include it in the report until final closure. We also continue to include data from prior years for closed sites because, in general, the manufacturing and other activities of closed sites are moved to other operations.
The data were reviewed and analysed to determine the impacts on air, water and land. These impacts were compared to the impacts in previous years to assess our performance in the key areas of concern. In the process of providing 2003 data, GSK sites reviewed the data reported in 2002 and 2001. Corrections made as a result of this review improved the accuracy and consistency of the data and improved the comparability of the impacts from year to year. A thorough review of the computations and factors used in arriving at the reported figures was also undertaken. For these reasons, the 2001 baseline and 2002 data have been modified for certain performance measures. This is most evident in the new baseline and modified data for carbon dioxide. The other significant changes in the 2001 baseline data were ozone depletion potential, volatile organic compounds, wastewater chemical oxygen demand and non-hazardous waste. Minor changes were made to the 2001 baselines for energy, hazardous waste and waste recycled.
For each parameter the stacked bar chart gives the absolute amount of the parameter with the components shown by the stack. The line graph gives the same value normalised by sales and displayed relative to the 2001 baseline.
The 2003 data show that GSK is on track to meet the 2005 targets for most key performance indicators although we need to focus on decreasing our volatile organic compound emissions, wastwater pollution and hazardous waste and increasing our waste recycling efforts. |
